To access this element change to forms mode OFF
Grant Award View - GA278327
Development of a therapeutic monoclonal antibody
GA ID:
GA278327
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
7-Dec-2022
Publish Date:
9-Jan-2023
Category:
Medical Research
Grant Term:
1-Jan-2023 to 31-Dec-2025
Value (AUD):
$867,242.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 21/22 1.1 Health and Medical Research
Grant Program:
Development Grants
Grant Activity:
Development of a therapeutic monoclonal antibody
Purpose:
This project specifically relates to the development of a product - a humanised monoclonal antibody. The project has now reached an early proof-of-principle-stage of product development and represents a highly promising commercial opportunity for Australia, with annual sales of monoclonals exceeding $100 billion in 2021. To be able to progress our basic discoveries into a commercial product a humanised antibody is required.
GO ID:
GO Title:
NHMRC Development Grants 2022 for funding in 2023
Internal Reference ID:
2022/GNT2022625
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
The Garvan Institute of Medical Research
Recipient ABN:
62 330 391 937
Grant Recipient Location
Suburb:
Darlinghurst
Town/City:
Darlinghurst
Postcode:
2010
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW
Postcode:
Country:
AUSTRALIA